Q32 Bio’s stock crashes after atopic dermatitis fail, alopecia trial snafu

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Opinion | Is Your Patient Married? Check Their Spouse’s Blood Pressure, Too

Varghese is an assistant research professor. Lu is a postdoctoral researcher. Li is a postdoctoral fellow. Hypertension, the leading cause of death from heart disease

December 19, 2023

The contribution of transcription factor ROB1 to the pathophysiology of C. albicans-induced candidal infections

Researchers evaluated the function of the zinc finger transcription factor ROB1 and its two phenotypically distinct alleles in the pathogenesis of Candida albicans infections.

June 20, 2023

Merck opens London lab as it makes push into immunology and the UK

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.